Form 4: Travere Therapeutics Director John A. Orwin Acquires Shares and Options

Director John A. Orwin acquired 6,500 shares of common stock and options to purchase 19,500 shares of Travere Therapeutics, Inc. on May 8, 2024.

Summary

• On May 8, 2024, John A. Orwin, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Orwin directly owns 28,875 shares of common stock.
• Orwin also acquired options to purchase 19,500 shares of common stock at an exercise price of $6.82.
• The options vest over a one-year period and expire on May 7, 2034.
• The acquisition was made under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction related to director compensation. The director increasing their holdings is a mildly positive signal, but it's not a major event.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (officers, directors, or those holding 10% or more of a company's shares) trade in their company's stock. These filings provide transparency into insider activity and can be monitored for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates